Correction: Survival of myelodysplastic syndrome patients after azacitidine therapy

• by Kanticha Thammagul, Suppalux Limpiwattakee, Pichika Chantrathammachart, Teeraya Puavilai, Suporn Chuncharunee, Pimjai Niparuck

• September 26, 2026

A New Era for Pancreatic Cancer: How Baptist Health Research Helped Get Us Here

Pancreatic adenocarcinoma, the most common form of pancreatic cancer, accounts for roughly 90 to 95 percent of cases. It's notoriously difficult to catch early, because symptoms often don't appear until the disease has already spread

• by

• September 24, 2026

• 11 min

Daratumumab ± pomalidomide maintenance after salvage autologous transplantation in relapsed multiple myeloma: a phase 2 study

• by Oren Pasvolsky, Bruno Almeida Costa, Yosra M. Aljawai, Krina K. Patel, Qaiser Bashir, Dawen Sui, Samer A. Srour, Mark R. Tanner, Uday R. Popat, Neeraj Y. Saini, Chitra Hosing, Jeremy L. Ramdial, Hans C. Lee, Gregory P. Kaufman, Sheeba K. Thomas, Donna M. Weber, Melody Becnel, Guilin Tang, Robert Z. Orlowski, Richard E. Champlin, Yago Nieto, Elizabeth J. Shpall, Muzaffar H. Qazilbash

• September 26, 2026

Deep learning-based segmentation of peritoneal cancer index regions from CT imaging

• by Pieter C. Gort, Lotte J. S. Fleurkens-Ewals, Lenah D. Kampmeijer, Anna F. van Herwijnen, Marion W. Tops-Welten, Cris H. B. Claessens, Joost Nederend, Ignace H. J. T. De Hingh, Max J. Lahaye, Misha D. P. Luyer, Fons van der Sommen

• September 27, 2026